Literature DB >> 12736732

Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis.

.   

Abstract

Multiple sclerosis can be associated with trigeminal neuralgia which is often difficult to treat in this specific condition. We performed an open prospective trial on the efficacy and safety of the prostaglandin-E1-analogue misoprostol (600 microg per day) in the reduction of attack frequency and pain intensity in patients with refractory trigeminal neuralgia associated with multiple sclerosis. Eighteen patients completed the study period and 14 of them showed a reduction of more than 50 % in attack frequency and intensity beginning five days after treatment onset. There were only mild and transient drug related side effects in three patients. One patient stopped taking misoprostol after the study period because of severe menorrhagia. Our results suggest that misoprostol is effective and safe in the treatment of this specific type of refractory trigeminal neuralgia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736732     DOI: 10.1007/s00415-003-1032-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis.

Authors:  Theodore R Brown; April Slee
Journal:  Int J MS Care       Date:  2015 Mar-Apr

Review 2.  Multiple sclerosis-related central pain disorders.

Authors:  Turo J Nurmikko; Sameer Gupta; Kate Maclver
Journal:  Curr Pain Headache Rep       Date:  2010-06

Review 3.  Pharmacological management of pain in patients with multiple sclerosis.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

4.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 5.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 6.  Role of cannabinoids in multiple sclerosis.

Authors:  John P Zajicek; Vicentiu I Apostu
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

Review 7.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 8.  [Ins and outs of neurologic therapy for chronic pain].

Authors:  S Sternberg; F Birklein; A May
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

Review 9.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Authors:  Ahmad Fallata; Amber Salter; Tuula Tyry; Gary R Cutter; Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2017 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.